Sarepta Therapeutics (SRPT) was one of the most dramatic and volatile biotech story lines in 2016. My track record was mixed. I had the correct read of Janet Woodcock’s “approve Exondys” mindset coming out of what looked, on the surface, like a negative FDA advisory committee meeting. Exondys was approved.
